Last reviewed · How we verify
CMV-MVA Triplex Vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CMV-MVA Triplex Vaccine (CMV-MVA Triplex Vaccine) — Masonic Cancer Center, University of Minnesota.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CMV-MVA Triplex Vaccine TARGET | CMV-MVA Triplex Vaccine | Masonic Cancer Center, University of Minnesota | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CMV-MVA Triplex Vaccine CI watch — RSS
- CMV-MVA Triplex Vaccine CI watch — Atom
- CMV-MVA Triplex Vaccine CI watch — JSON
- CMV-MVA Triplex Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). CMV-MVA Triplex Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/cmv-mva-triplex-vaccine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing